Acute Lymphocytic Leukemia with Novartis Kymriah, Pediatric
Kymriah, developed by Novartis, is a type of immunotherapy for pediatric patients with Acute Lymphocytic Leukemia (ALL). Through Kymriah therapy, a patient's T-cells are genetically reprogrammed to fight cancer cells.
3 Result(s)
Distance
13 Miles
680 Miles
2252 Miles
Details